Project Grant R43CA250780

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to the Translational Genomics Research Institute (TGen) to investigate the use of a senescent cell targeted antibody (SIWA318) for improving the efficacy of standard chemotherapy or immune checkpoint inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 2-year award include: 1) Determining the...

This $405,000 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports Panorama Research Incorporated's development of a novel antibody-based immunotherapy to enhance ovarian tumor responses to treatment. The project aims to create a switchable split superantigen fused with antibodies targeting binary tumor-specific receptors, with the goal of boosting the effectiveness of immunotherapy for ovarian cancer patients. As a...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $115,000.00 to Navrogen Inc. to characterize HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity via the Fc receptor (CD16A). The goal is to develop pharmaceutical antagonists that can overcome the immunosuppressive effects of HIO-2, which correlate with worse progression-free survival after treatment with certain cancer antibody...

The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...

This federal Project Grant award of $1,146,618.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mucommune LLC supports the development of in vivo-engineered chimeric antigen receptor (CAR) T-cell therapies for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services being delivered under this award include: Engineering highly potent yet specific CAR-T cells against the B7-H3 antigen, which is overexpressed in PDAC, using a novel...

This federal Project Grant award in the amount of $400,000.00 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Oncotab, Inc., a research-focused company based in Waxhaw, North Carolina. The funding will support the development of optimized targeted radiotherapy approaches for the treatment of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer with a 5-year survival rate under 9%. The key focus of this project is to...

This $641,936 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a novel approach using engineered chimeric antigen receptor (CAR)-neutrophils to treat glioblastoma, the most aggressive type of brain cancer. The principal investigators at Purdue University will harness synthetic biology, machine learning, and in vivo models to investigate programming tumor-associated neutrophils as anti-tumor effector cells. The proposed strategy...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The proposed research aims to engineer CAR-T cells that can secrete an optimized form of a VIP receptor antagonist to counter the immunosuppressive effects of the PDAC tumor microenvironment. The award supports a "fast-track" SBIR...

This $639,098 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop an effective treatment for metastatic pancreatic cancer. The award supports research by the University of Rochester to target both intrinsic and extrinsic barriers that promote metastasis and treatment resistance in pancreatic ductal adenocarcinoma (PDAC). The key products or services to be delivered include: Investigating a novel combination therapy of localized...

This Project Grant award, provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), supports research to identify predictive markers of response and treatment effects for a combination therapy regimen in treatment-naive metastatic pancreatic cancer. The $109,080 grant funds a phase II randomized controlled trial to evaluate the efficacy of the combination therapy, which includes the CXCR4 inhibitor motixafortide, the anti-PD1 agent cemiplimab, gemcitabine, and...